#SSRIs

A recent study published in the Journal of Positive Psychology has uncovered a striking link between optimism and the likelihood of responding positively to selective serotonin reuptake inhibitors (SSRIs), a mainstay medication for major depressive disorder. The research suggests that individuals with a more optimistic outlook are not only better positioned to benefit from these antidepressants, but that increases in optimism during treatment also significantly raise the chances of recovery—a finding with important implications for the future of mental health care in Thailand and globally (PsyPost).

A widely-prescribed antidepressant may significantly shorten lifespan—by up to six years—according to recent findings circulated by the international medical community. The claim, based on a new research review highlighted by several medical news outlets and summarized in a viral Yahoo Lifestyle article, is igniting debate among doctors, mental health professionals, and patients in Thailand and around the world over the safety and prescription practices of this common medication.

The backdrop of this news is the widespread and growing use of antidepressant drugs, especially selective serotonin reuptake inhibitors (SSRIs), which include widely-recognized names such as sertraline, fluoxetine, and paroxetine. With depression and anxiety rates rising globally—including in Thailand, where mental health awareness has increased sharply in the aftermath of the Covid-19 pandemic—these medications are standard tools for primary care doctors and psychiatrists alike [World Health Organization].